JAK2 and acute myeloid leukemia: DNMT3A mutations were unusually rare (6 patients), this suggests that patients with AML and MF, may either have a distinct foundational mutational event, or a clone with higher fitness (such as JAK2) outcompetes pre-existing DNMT3A clones.